 |
Top 10 Alzheimer's Disease treatment startups
Updated: April 19, 2024 |
Startups in the field of Alzheimer's disease treatment are developing innovative technologies such as precision medicine, gene therapies, immunotherapies, and neurostimulation techniques to target the underlying causes and symptoms of the disease.
1
Country: USA | Funding: $622M
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
2
Country: USA | Funding: $448.5M
Amylyx Pharmaceutical is a pharmaceutical company that specializes in providing solutions on Alzheimer’s and other diseases of the brain.
Amylyx Pharmaceutical is a pharmaceutical company that specializes in providing solutions on Alzheimer’s and other diseases of the brain.
3
Country: USA | Funding: $374M
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
4
Country: USA | Funding: $295.1M
Acumen Pharmaceuticals is focused on discovering and developing best in class therapeutics and diagnostics for Alzheimer’s disease.
Acumen Pharmaceuticals is focused on discovering and developing best in class therapeutics and diagnostics for Alzheimer’s disease.
5
Country: USA | Funding: $257.4M
Codiak Biosciences is developing multiple platforms for both therapeutic and diagnostic applications based on a growing appreciation for exosome biology.
Codiak Biosciences is developing multiple platforms for both therapeutic and diagnostic applications based on a growing appreciation for exosome biology.
6
Country: USA | Funding: $225M
Cortexyme is developing novel treatments for altering the course of Alzheimer's and other degenerative diseases.
Cortexyme is developing novel treatments for altering the course of Alzheimer's and other degenerative diseases.
7
Country: USA | Funding: $194.5M
Alector is a hypothesis-driven, neurology-focused startup that’s pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. We are combining state-of-the-art antibody technology and recent discoveries in neuro-immunology and human genetics to develop a broad platform of novel therapeutics that harness the immune system to fight dementia and neurodegeneration.
Alector is a hypothesis-driven, neurology-focused startup that’s pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. We are combining state-of-the-art antibody technology and recent discoveries in neuro-immunology and human genetics to develop a broad platform of novel therapeutics that harness the immune system to fight dementia and neurodegeneration.
8
Country: USA | Funding: $185M
LEXEO Therapeutics develops gene therapy for the world's most devastating diseases
LEXEO Therapeutics develops gene therapy for the world's most devastating diseases
9
Country: Netherlands | Funding: €160M
VectorY Therapeutics develops gene therapies against amyotrophic lateral sclerosis (ALS) and Alzhiemer’s disease.
VectorY Therapeutics develops gene therapies against amyotrophic lateral sclerosis (ALS) and Alzhiemer’s disease.
10
Country: USA | Funding: $161M
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Ad
Advertise your startup
11
Country: USA | Funding: $140M
Alzheon is committed to developing innovative medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Our Alzheon’s drug development platform which comprises proprietary chemistries, robust clinical efficacy and safety datasets in patients and genetically-defined subpopulations, and the ability to optimize molecules to have the desired therapeutic attributes.
Alzheon is committed to developing innovative medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Our Alzheon’s drug development platform which comprises proprietary chemistries, robust clinical efficacy and safety datasets in patients and genetically-defined subpopulations, and the ability to optimize molecules to have the desired therapeutic attributes.
12
Country: USA | Funding: $140M
BioXcel Therapeutics is a clinical stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology.
BioXcel Therapeutics is a clinical stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology.
13
Country: USA | Funding: $137.4M
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
14
Country: South Korea | Funding: $137M
D&D Pharmatech is a biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty. This corporate structure creates a unique opportunity to accelerate translation of cutting-edge research into lifesaving therapeutic products for patients. The company’s product pipeline focuses on a range of indications including neurodegenerative and fibrotic diseases.
D&D Pharmatech is a biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty. This corporate structure creates a unique opportunity to accelerate translation of cutting-edge research into lifesaving therapeutic products for patients. The company’s product pipeline focuses on a range of indications including neurodegenerative and fibrotic diseases.
15
Country: USA | Funding: $134.1M
We use genomic data to find better drugs, faster. We find new cures for brain diseases 1000X more cheaply and quickly using our proven network algorithms.
We use genomic data to find better drugs, faster. We find new cures for brain diseases 1000X more cheaply and quickly using our proven network algorithms.
16
Country: Denmark | Funding: $77.9M
Muna develops transformative therapeutics to preserve brain function and enhance resilience to neurodegenerative diseases
Muna develops transformative therapeutics to preserve brain function and enhance resilience to neurodegenerative diseases
17
Country: USA | Funding: $60.4M
Neurotrack is a digital health company dedicated to the development of non-invasive cognitive health assessment tools that will enable earlier and more effective evaluation of patients who may be at risk for cognitive decline, and help advance research of treatments for cognitive diseases, including Alzheimer's. We are driven by the belief that cognitive decline and conditions like Alzheimer’s disease can be beaten if detected early. Our energy and passion goes into developing digital tools to facilitate groundbreaking change.
Neurotrack is a digital health company dedicated to the development of non-invasive cognitive health assessment tools that will enable earlier and more effective evaluation of patients who may be at risk for cognitive decline, and help advance research of treatments for cognitive diseases, including Alzheimer's. We are driven by the belief that cognitive decline and conditions like Alzheimer’s disease can be beaten if detected early. Our energy and passion goes into developing digital tools to facilitate groundbreaking change.
18
Country: UK | Funding: $40.3M
Wren Therapeutics is a biopharmaceutical company based, focused on drug discovery and development for protein misfolding diseases.
Wren Therapeutics is a biopharmaceutical company based, focused on drug discovery and development for protein misfolding diseases.
19
Country: USA | Funding: $40.3M
T3D Therapeutics is a company developing remedial therapeutics for Alzheimer’s disease and other CNS disorders.
T3D Therapeutics is a company developing remedial therapeutics for Alzheimer’s disease and other CNS disorders.
20
Country: Belgium | Funding: €29.7M
Amyl Therapeutics unique technology offers a curative solution for all forms of amyloid mediated diseases
Amyl Therapeutics unique technology offers a curative solution for all forms of amyloid mediated diseases
21
Country: Canada | Funding: $25.2M
Optina Diagnostics develops technology for the early detection of disease through the eye.
Optina Diagnostics develops technology for the early detection of disease through the eye.
22
Country: USA | Funding: $24.7M
Altoida Medical Device (AMD) provides health care professionals objective measurements of cognitive performance.
Altoida Medical Device (AMD) provides health care professionals objective measurements of cognitive performance.
23
Country: USA | Funding: $21.2M
NeuroVision is developing a noninvasive, quick, and inexpensive retinal imaging test for the early detection and diagnosis of Alzheimer’s disease. Our proprietary technology allows us to image amyloid beta plaque (the hallmark sign of the disease) in the retina.
NeuroVision is developing a noninvasive, quick, and inexpensive retinal imaging test for the early detection and diagnosis of Alzheimer’s disease. Our proprietary technology allows us to image amyloid beta plaque (the hallmark sign of the disease) in the retina.
24
Country: Spain
Araclon Biotech is a company dedicated to the research and development of therapies and diagnostic methods to be applied to degenerative diseases, currently focusing on Alzheimer’s disease.
Araclon Biotech is a company dedicated to the research and development of therapies and diagnostic methods to be applied to degenerative diseases, currently focusing on Alzheimer’s disease.
25
Country: USA | Funding: $14.4M
AgeneBio is developing innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function.
AgeneBio is developing innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function.
26
Country: South Korea | Funding: $13.4M
Through use of technology in which measures and modulates brain signals, we develop research protocols that improve cognitive functions. We provide meaningful information retrieved from the wearable devices through analysis of brain signal big data. With this big data, we predict and diagnose the stages of the neurological diseases such as Alzheimer’s disease and mild cognitive impairment.
Through use of technology in which measures and modulates brain signals, we develop research protocols that improve cognitive functions. We provide meaningful information retrieved from the wearable devices through analysis of brain signal big data. With this big data, we predict and diagnose the stages of the neurological diseases such as Alzheimer’s disease and mild cognitive impairment.
27
Country: USA | Funding: $10M
Telocyte focuses on the development of telomerase therapy to treat Alzheimer's disease.
Telocyte focuses on the development of telomerase therapy to treat Alzheimer's disease.
28
Country: UK | Funding: $120K
We use Machine learning to automatically derive accurate brain features (e.g. the volume of the hippocampus) from brain scans and compare them to a normative population. We also provide handy 2D and 3D visualisations of brain features. This not only saves time to neuroradiologists but also empowers them to make highly accurate reports, by using the latest techniques and findings in neurosciences
We use Machine learning to automatically derive accurate brain features (e.g. the volume of the hippocampus) from brain scans and compare them to a normative population. We also provide handy 2D and 3D visualisations of brain features. This not only saves time to neuroradiologists but also empowers them to make highly accurate reports, by using the latest techniques and findings in neurosciences
29
Country: USA
Iluminos Therapeutics creates compounds that have the potential to treat neurodegenerative disease, in particular Alzheimer’s disease.
Iluminos Therapeutics creates compounds that have the potential to treat neurodegenerative disease, in particular Alzheimer’s disease.
30
Country: Germany
Priavoid envisions curing neurological disorders by developing innovative treatment strategies based on a new class of orally available compounds. Focusing on indications with significant unmet medical need Priavoid applies the therapeutic concept to Alzheimer’s disease (AD), neuropathic pain and other neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), tauopathies, Parkinson’s disease (PD), and Huntington’s disease (HD).
Priavoid envisions curing neurological disorders by developing innovative treatment strategies based on a new class of orally available compounds. Focusing on indications with significant unmet medical need Priavoid applies the therapeutic concept to Alzheimer’s disease (AD), neuropathic pain and other neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), tauopathies, Parkinson’s disease (PD), and Huntington’s disease (HD).
31
Country: USA
LGT develops telomerase therapy (hTERT gene therapy) that cures Alzheimer’s disease and aging
LGT develops telomerase therapy (hTERT gene therapy) that cures Alzheimer’s disease and aging
32
Country: USA
Preclinical stage MedTech company developing an early diagnostic and a device to prevent Alzheimer's disease
Preclinical stage MedTech company developing an early diagnostic and a device to prevent Alzheimer's disease
33
Country: UK
Perdeca offers two digital health products. One helps anyone to make better decisions. The other assists families and carers of patients living with dementia including Alzheimer’s to join them in memory re-connection sessions.
Perdeca offers two digital health products. One helps anyone to make better decisions. The other assists families and carers of patients living with dementia including Alzheimer’s to join them in memory re-connection sessions.